Several brokerages have updated their recommendations and price targets on shares of Gilead Sciences (NASDAQ: GILD) in the last few weeks:

  • 10/20/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock.
  • 10/19/2017 – Gilead Sciences was given a new $96.00 price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 10/19/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at William Blair.
  • 10/19/2017 – Gilead Sciences had its price target raised by analysts at Leerink Swann from $84.00 to $85.00. They now have a “market perform” rating on the stock.
  • 10/19/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 10/18/2017 – Gilead Sciences was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise continued to witness slowdown as a result of competitive and pricing pressure. Higher discounts and payer mix continue to hurt sales. The company expects that the persistent decline in HCV patient starts will impact sales along with increased competition which will impact both patient share and pricing. While the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens, Gilead will lose exclusivity for Viread in 2017 in some countries which should impact sales. TOn a positive note, Gilead recently acquired Kite Pharma to foray into the CAR T therapy space which represents immense potential at this juncture . Shares of the company have outperformed the industry so far in 2017.”
  • 10/13/2017 – Gilead Sciences was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $91.98 price target on the stock.
  • 10/11/2017 – Gilead Sciences had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $90.00 price target on the stock.
  • 10/6/2017 – Gilead Sciences had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $83.00 price target on the stock, up previously from $77.00.
  • 10/5/2017 – Gilead Sciences is now covered by analysts at Jefferies Group LLC. They set a “positive” rating on the stock.
  • 10/5/2017 – Gilead Sciences is now covered by analysts at Oppenheimer Holdings, Inc.. They set a “market perform” rating on the stock.
  • 10/5/2017 – Gilead Sciences is now covered by analysts at CIBC. They set a “market perform” rating on the stock.
  • 10/5/2017 – Gilead Sciences had its price target raised by analysts at Leerink Swann from $87.00 to $89.00. They now have a “market perform” rating on the stock.
  • 10/4/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $93.00 price target on the stock.
  • 10/4/2017 – Gilead Sciences had its price target lowered by analysts at Bank of America Corporation from $87.00 to $86.00. They now have a “neutral” rating on the stock.
  • 9/29/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Mizuho.
  • 9/20/2017 – Gilead Sciences had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $87.00 price target on the stock, up previously from $82.00.
  • 9/14/2017 – Gilead Sciences is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $94.00 price target on the stock.
  • 9/13/2017 – Gilead Sciences was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 9/11/2017 – Gilead Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which has dampened of late. We note that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives.  Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU. Shares of the company have outperformed the industry so far in 2017.”
  • 9/7/2017 – Gilead Sciences was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 9/7/2017 – Gilead Sciences was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 9/6/2017 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $73.00 to $81.00. They now have a “market perform” rating on the stock.
  • 9/6/2017 – Gilead Sciences was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $89.27 price target on the stock.
  • 9/6/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Berenberg Bank. They now have a $96.00 price target on the stock, up previously from $86.00.
  • 9/4/2017 – Gilead Sciences was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $86.44 price target on the stock.
  • 8/31/2017 – Gilead Sciences was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $100.00 price target on the stock.
  • 8/31/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at William Blair. They now have a $87.00 price target on the stock.
  • 8/31/2017 – Gilead Sciences had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $81.00 price target on the stock.
  • 8/31/2017 – Gilead Sciences had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $81.00 price target on the stock, up previously from $73.00.
  • 8/31/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $90.00 price target on the stock.
  • 8/29/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $85.00 price target on the stock, up previously from $79.00.
  • 8/29/2017 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $87.00 price target on the stock.
  • 8/29/2017 – Gilead Sciences was given a new $86.00 price target on by analysts at Berenberg Bank. They now have a “buy” rating on the stock.
  • 8/28/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 8/28/2017 – Gilead Sciences was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $82.15 price target on the stock.
  • 8/28/2017 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 8/28/2017 – Gilead Sciences was given a new $79.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 80.17 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm has a market cap of $104.70 billion, a P/E ratio of 8.71 and a beta of 1.14. The company’s 50 day moving average price is $82.53 and its 200 day moving average price is $72.83.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue was down 8.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.08 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post $8.77 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.59%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In related news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 446,819 shares of company stock valued at $36,338,919. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.